Ann Arfsten

Medicine · Health Sciences

24h-index2.9kcitations45works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Coagulation and Thrombosis Mechanisms(12), Receptor Mechanisms and Signaling(10), Platelet Disorders and Treatments(7), RNA and protein synthesis mechanisms(6), Atrial Fibrillation Management and Outcomes(4)

Publications45 total

Discovery of ITMN-14440: A Pirfenidone Analog with Improved Pharmacokinetics, Anti-Fibrotic Efficacy and Reduced Gastric Side Effects
18th International Colloquium on Lung and Airway Fibrosis·2014
Hepatitis C Genotype 1a Replicon Improved Through Introduction of Fitness Mutations
BioTechniques·2012· 6 citedOpen Access
Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution
Antimicrobial Agents and Chemotherapy·2011· 38 citedOpen Access
1228 CHARACTERIZATION OF NOVEL, HIGHLY POTENT NS5A INHIBITORS WITH QD DOSING POTENTIAL AND ROBUST ACTIVITY IN AN HCV CHIMERIC ANIMAL MODEL
Journal of Hepatology·2011· 3 cited
ChemInform Abstract: Design, Synthesis and Discovery of 1‐(2‐(6‐Chloro‐3‐methylsulfonyl)‐naphthyl)‐1H‐pyrazole‐5‐carboxylamides as Highly Potent Factor Xa Inhibitors.
ChemInform·2010
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor
Bioorganic & Medicinal Chemistry Letters·2009· 105 citedOpen Access
Design, Synthesis and Discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as Highly Potent Factor Xa Inhibitors
Chemical and Pharmaceutical Bulletin·2009· 4 citedOpen Access
Inhibition of Prothrombinase and Not Soluble Factor Xa (fXa) Predicts Efficacy of fXa Inhibitors in an In Vivo Model of Deep Vein Thrombosis.
Blood·2006
Parallel synthesis and structure–activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors
Bioorganic & Medicinal Chemistry Letters·2004· 11 cited
N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors
Bioorganic & Medicinal Chemistry Letters·2004· 17 citedOpen Access
1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs
Bioorganic & Medicinal Chemistry Letters·2004· 25 citedOpen Access
1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors
Bioorganic & Medicinal Chemistry Letters·2004· 52 citedOpen Access
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity
Bioorganic & Medicinal Chemistry Letters·2004· 24 citedOpen Access
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs
Bioorganic & Medicinal Chemistry Letters·2004· 25 citedOpen Access
Inhibition of Purified Factor Xa Amidolytic Activity May Not Be Predictive of Inhibition of In Vivo Thrombosis
Arteriosclerosis Thrombosis and Vascular Biology·2003· 14 cited
Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors
Bioorganic & Medicinal Chemistry Letters·2003· 18 citedOpen Access
Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the <i>N</i>-α-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors
Journal of Medicinal Chemistry·1997· 18 citedOpen Access
Effect of Ca <sup>2+</sup> on GP IIb-IIIa Interactions With Integrilin
Circulation·1997· 248 cited
Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists
Journal of Medicinal Chemistry·1997· 22 citedOpen Access
Non-Peptide RGD Surrogates Which Mimic a Gly-Asp β-Turn:  Potent Antagonists of Platelet Glycoprotein IIb−IIIa
Journal of Medicinal Chemistry·1997· 49 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Robert M. Scarborough(25), Uma Sinha(12), Bing‐Yan Zhu(12), Penglie Zhang(10), Zhaozhong J. Jia(10), John Lewicki(8), Susan Edwards(7), Athiwat Hutchaleelaha(7), Stanley J. Hollenbach(7), Wenrong Huang(6), Ting Su(6), J G Porter(5), Jack W. Rose(5), Erick A. Goldman(5), John Woolfrey(5), Joseph L. Lambing(5), Forrest Fuller(4), Dale B. Schenk(4), M.A. Naughton(4), Yonghong Song(4)